Takeda has withdrawn the biologics licence application (BLA) submitted to the US Food and Drug Administration (FDA) for TAK-003, a tetravalent dengue vaccine candidate.

The vaccine is based on a live-attenuated dengue serotype 2 virus.

This development comes after the company held talks with the regulatory agency on data collection issues that cannot be resolved within the review cycle of this application.

The prospective strategy for the vaccine in the US will be further assessed based on the requirements of travellers as well as those residing in dengue-endemic regions of the country, such as Puerto Rico.

TAK-003’s safety and efficacy were validated in a Phase III clinical trial carried out over 4.5 years in more than 20,000 children and adolescents from eight dengue-endemic regions.

The vaccine received approval in the EU, UK, Thailand, Argentina, Indonesia and Brazil, with further approvals anticipated.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Takeda vaccines business unit president Gary Dubin stated: “Our clinical programme was designed to account for the complex global nature of dengue, and data from our 4.5-year trial has built confidence in TAK-003’s ability to help provide long-term protection against dengue, with a positive benefit and risk profile regardless of baseline serostatus. 

“The urgent global need to combat the growing burden of dengue remains, and we will continue to progress regulatory reviews and provide access for people living in and travelling to dengue-endemic areas while we work to determine next steps in the US.”

The company has also entered a discovery partnership and licence deal with F-star Therapeutics to develop multi-specific antibodies.